Hong Kong, September 14, 2018
Hua Medicine, a China-based drug development company with a focus on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, successfully completed its initial public offering, or IPO, and listing on the Hong Kong Stock Exchange.
The IPO priced at HK$8.28 per share, with a total offering size of 104,756,000 shares, before over-allotments, raising approximately HK$867 million with a market capitalization of approximately HK$8,710 million immediately after the IPO.
The Global Sponsors for the IPO were Goldman Sachs (Asia) L.L.C. and CLSA Capital Markets Limited, the Joint Bookrunners were Goldman Sachs (Asia) L.L.C., CLSA Limited and UBS AG Hong Kong Branch and the Joint Lead Managers were Goldman Sachs (Asia) L.L.C, CLSA Limited, UBS AG Hong Kong Branch and Guotai Junan Securities (Hong Kong) Limited.
This press release does not, and is not intended to be or constitute an offer to sell, or an invitation or solicitation of an offer to buy or subscribe for, the Hua Medicine in the United States or any other jurisdiction. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws of the United States and may not be offered and sold within the United States absent an applicable exemption from the registration requirements of the Securities Act. No public offering of the securities referred to herein will be made in the United States or in any jurisdiction outside of Hong Kong.
沪公网安备 31011502013809号 Privacy Statement Terms of Use
